Competing/conflicts of interest: R Troutbeck and A van Heerdon were previous Novartis medical retinal fellows, and R Bunting is the current Novartis medical retinal fellow. R Guymer is on the Novartis Australia advisory board.
Ranibizumab therapy for choroidal neovascularization secondary to non-age-related macular degeneration causes
Version of Record online: 23 DEC 2011
© 2011 The Authors. Clinical and Experimental Ophthalmology © 2011 Royal Australian and New Zealand College of Ophthalmologists
Clinical & Experimental Ophthalmology
Volume 40, Issue 1, pages 67–72, January/February 2012
How to Cite
Troutbeck, R., Bunting, R., van Heerdon, A., Cain, M. and Guymer, R. (2012), Ranibizumab therapy for choroidal neovascularization secondary to non-age-related macular degeneration causes. Clinical & Experimental Ophthalmology, 40: 67–72. doi: 10.1111/j.1442-9071.2011.02719.x
Funding sources: CERA receives Operational Infrastructure Support from the Victorian Government.
- Issue online: 5 FEB 2012
- Version of Record online: 23 DEC 2011
- Accepted manuscript online: 17 OCT 2011 08:49AM EST
- Received 17 July 2011; accepted 22 September 2011.
- choroidal neovascular membrane;
- multifocal choroiditis;
Background: To investigate the efficacy of ranibizumab therapy for choroidal neovascular (CNV) membranes secondary to conditions other than macular degeneration.
Design: Prospective case series conducted at the Royal Victorian Eye and Ear Hospital.
Participants: Twelve-month follow-up data for 41 patients with CNV recruited from the outpatient clinic from May 2008 to April 2010 is presented. Fifteen patients had myopia, seven had multifocal choroiditis, and eight had other primary causes.
Methods: All patients had visual acuity, fluorescein angiogram and optical coherence tomography performed at the initial visit (baseline). Ranibizumab was injected with a standard sterile technique. Patients were reviewed after 1 month, and further injections were given at the treating doctors' discretion.
Main Outcome Measures: Change in visual acuity and central macular thickness at 12 months was compared with baseline for each of the groups. Local and systemic adverse outcomes were recorded.
Results: Analysis was stratified by primary pathology. On average, 40%, 43% and 25% of patients with myopia, multifocal choroiditis and ‘other’ pathologies, respectively, experienced a three or more line improvement in vision. The average number of injections in 12 months was 4.2 for the entire group. Central macular thickness significantly decreased in the 12-month period for the combined group (P = 0.03). No patient had an adverse systemic side-effect; however, there was one case of endophthalmitis.
Conclusions: Ranibizumab is an effective treatment for CNV secondary to non-age-related macular degeneration causes, with most patients gaining an improvement in the first 2 months following injection.